Ruoke Wang
YOU?
Author Swipe
View article: Knockdown of Serine–Arginine Protein Kinase 3 Impairs Sperm Development in Spodoptera frugiperda
Knockdown of Serine–Arginine Protein Kinase 3 Impairs Sperm Development in Spodoptera frugiperda Open
Lepidopterans produce two distinct types of sperm: nucleated eupyrene sperm for fertilization and anucleate apyrene sperm for auxiliary functions. However, the mechanisms underlying sperm dimorphism in fall armyworm Spodoptera frugiperda r…
View article: Efficient metabolic fingerprinting profiling of extracellular vesicles for precise cancer diagnosis and treatment monitoring
Efficient metabolic fingerprinting profiling of extracellular vesicles for precise cancer diagnosis and treatment monitoring Open
Breast cancer is the most prevalent cancer among women globally, underscoring the need for accurate prognostic and predictive biomarkers. Extracellular vesicles (EVs), carrying bioactive molecules such as proteins and miRNAs, have emerged …
View article: DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection
DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection Open
DS-Cav1, SC-TM, and DS2 are distinct designer pre-fusion F proteins (pre-F) of respiratory syncytial virus (RSV) developed for vaccines. However, their immunogenicity has not been directly compared. In this study, we generated three recomb…
View article: Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies
Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies Open
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its Omicron subvariants drastically amplifies transmissibility, infectivity, and immune escape, mainly due to their resistance to most neutralizing antibodie…
View article: Ultrahigh-potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration
Ultrahigh-potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration Open
Despite substantial progress in antiretroviral therapy (ART) effectively suppressing HIV-1 replication in the bloodstream, a cure for HIV remains elusive. Existing antiviral drugs pose limitations, including lifelong medication, frequent a…
View article: Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants
Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants Open
The omicron variants of SARS-CoV-2 have substantial ability to escape infection- and vaccine-elicited antibody immunity. Here, we investigated the extent of such escape in nine convalescent patients infected with the wild-type SARS-CoV-2 d…
View article: Breakthrough infection with Omicron subvariant BF.7 induces broadly neutralizing antibodies to SARS-CoV-2 variants including XBB lineage
Breakthrough infection with Omicron subvariant BF.7 induces broadly neutralizing antibodies to SARS-CoV-2 variants including XBB lineage Open
Since China eased its COVID-19 response strategies in late 2022, we have been witnessing a rapid and wide spread of SARS-CoV-2 infection across the major cities, including capital Beijing, where Omicron subvariant BF.7 has been dominating …
View article: Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses Open
As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading worldwide, development of antibodies and vaccines to confer broad and protective activity is a global priority. Here, we report on the identification of a specia…
View article: Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2 Open
Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating coronavirus disease 2019 (COVID-19), resulting in the emerg…
View article: SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2
SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2 Open
Striking number of mutations found in the spike protein of recently emerged SARS-CoV-2 Omicron subvariants BA.1, BA.2, BA.3 and BA.4/5 has raised serious concerns regarding the escape from current antibody therapies and vaccine protection.…
View article: Broadly neutralizing and protective nanobodies against diverse sarbecoviruses
Broadly neutralizing and protective nanobodies against diverse sarbecoviruses Open
As SARS-CoV-2 Omicron and other variants of concern continue spreading around the world, development of antibodies and vaccines to confer broad and protective activity is a global priority. Here, we report on the identification of a specia…
View article: RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants Open
With the rapid emergence and spread of SARS-CoV-2 variants, development of vaccines with broad and potent protectivity has become a global priority. Here, we designed a lipid nanoparticle-encapsulated, nucleoside-unmodified mRNA (mRNA-LNP)…
View article: A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants Open
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge and spread around the world, antibodies and vaccines to confer broad and potent neutralizing activity are urgently needed. Through the isolation an…
View article: Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression
Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression Open
Although progress has been made on constructing potent bi-specific broadly neutralizing antibody (bi-bNAb), few bi-bNAbs have been evaluated against HIV-1/AIDS in non-human primates (NHPs). Here, we report the efficacy of a tandem bi-bNAb,…
View article: Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection
Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection Open
The development of a safe and effective vaccine against SARS-CoV-2, the causative agent of pandemic coronavirus disease-2019 (COVID-19), is a global priority. Here, we aim to develop novel SARS-CoV-2 vaccines based on a derivative of less …
View article: Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies Open
Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against coronavirus disease 2019 (COVID-19). We isolated a large number of n…
View article: SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage
SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage Open
New SARS-CoV-2 variants continue to emerge from the current global pandemic, some of which can replicate faster and with greater transmissibility and pathogenicity. In particular, UK501Y.V1 identified in UK, SA501Y.V2 in South Africa, and …
View article: Single-dose immunization with a chimpanzee adenovirus-based vaccine induces sustained and protective immunity against SARS-CoV-2 infection
Single-dose immunization with a chimpanzee adenovirus-based vaccine induces sustained and protective immunity against SARS-CoV-2 infection Open
The development of an effective vaccine against SARS-CoV-2, the causative agent of pandemic coronavirus disease-2019 (COVID-19), is a global priority. Here, we present three chimpanzee adenovirus vaccines that express either the full-lengt…
View article: Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies Open
Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against coronavirus virus diseases 2019 (COVID-19). We isolated a large numb…
View article: Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
Potent human neutralizing antibodies elicited by SARS-CoV-2 infection Open
The pandemic caused by emerging coronavirus SARS-CoV-2 presents a serious global public health emergency in urgent need of prophylactic and therapeutic interventions. SARS-CoV-2 cellular entry depends on binding between the viral Spike pro…
View article: Development of a Potent and Protective Germline-Like Antibody Lineage Against Zika Virus in a Convalescent Human
Development of a Potent and Protective Germline-Like Antibody Lineage Against Zika Virus in a Convalescent Human Open
Zika virus (ZIKV) specific neutralizing antibodies hold great promise for antibody-based interventions and vaccine design against ZIKV infection. However, their development in infected patients remains unclear. Here, we applied next-genera…
View article: Development of a potent and protective germline-like antibody lineage against Zika virus in a convalescent human
Development of a potent and protective germline-like antibody lineage against Zika virus in a convalescent human Open
Zika virus (ZIKV) specific neutralizing antibodies hold a great promise for antibody-based interventions and vaccine design against ZIKV infection. However, their development in infected patients remain unknown. Here, we report on the dyna…